I agree Yel. They must have some control over when they receive unblinded data or acceptable reason to delay release so as not to risk being caught out by a please explain from ASX (as if they would do anything anyway). I asked the question but my email with investor services remains unanswered. Again I have to say the comms and PR in MSB appears to be wanting compared to other , companies but I guess they are focused on the science. I should at least get a thanks for playing reply .
Anyway, I believe if it’s good news or bad news there is an indication that COVID has delayed all schedules of works for most trials (so Q3 becoming Q1 is not out of the question), and there see to be no really good reason to prioritise rushing CLBP results analysis and reporting ahead of COVID ARDS which is tied to the Novartis cooling off period. This is the critical one and so should be top priority. Between this trial secondary analysis which was unplanned, CHF partnership negotiations and engaging the FDA over both of those and gvhd who has time for clbp either way? As SI said in the webcast any one of these products are a company maker on their own so we have 5 shots at goal. CLBP is a bonus and fallback esp as its always been stated a further trial will be needed vs getting an AA for another product so which is the priority? Anyway just my speculation we will see soon I hope.
- Forums
- ASX - By Stock
- MPC-06-ID Phase 3 results countdown
I agree Yel. They must have some control over when they receive...
-
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 99.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.5¢ | 18069 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 0.990 |
2 | 32880 | 0.985 |
4 | 71034 | 0.980 |
2 | 3059 | 0.975 |
7 | 145890 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.995 | 1132 | 1 |
1.000 | 9500 | 3 |
1.005 | 35000 | 1 |
1.010 | 58113 | 4 |
1.015 | 46100 | 3 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online